273 related articles for article (PubMed ID: 37983270)
1. Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders.
Raithatha SA; Hagel JM; Matinkhoo K; Yu L; Press D; Cook SG; Sharma G; Dhananjaya D; Jensen G; Lee JB; Cai C; Gallant J; Bains J; Tucker JE; Facchini PJ
J Med Chem; 2024 Jan; 67(2):1024-1043. PubMed ID: 37983270
[TBL] [Abstract][Full Text] [Related]
2. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
3. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.
Ezeaka UC; Kim HJJ; Laprairie RB
Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550
[TBL] [Abstract][Full Text] [Related]
4. DARK Classics in Chemical Neuroscience: Psilocybin.
Geiger HA; Wurst MG; Daniels RN
ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.
Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM
Eur Neuropsychopharmacol; 2021 Sep; 50():121-132. PubMed ID: 34246868
[TBL] [Abstract][Full Text] [Related]
6. The zebrafish for preclinical psilocybin research.
Syed OA; Tsang B; Gerlai R
Neurosci Biobehav Rev; 2023 Oct; 153():105381. PubMed ID: 37689090
[TBL] [Abstract][Full Text] [Related]
7. The Therapeutic Potential of Psilocybin.
Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
Molecules; 2021 May; 26(10):. PubMed ID: 34063505
[TBL] [Abstract][Full Text] [Related]
8. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
9. RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-
Bryson N; Alexander R; Asnis-Alibozek A; Ehlers MD
ACS Chem Neurosci; 2024 Jun; 15(12):2386-2395. PubMed ID: 38758589
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
Dinis-Oliveira RJ
Drug Metab Rev; 2017 Feb; 49(1):84-91. PubMed ID: 28074670
[TBL] [Abstract][Full Text] [Related]
12.
Jones NT; Wagner L; Hahn MCP; Scarlett CO; Wenthur CJ
Front Psychiatry; 2023; 14():1303365. PubMed ID: 38264637
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines.
Lenz C; Dörner S; Trottmann F; Hertweck C; Sherwood A; Hoffmeister D
Chembiochem; 2022 Jul; 23(13):e202200183. PubMed ID: 35483009
[TBL] [Abstract][Full Text] [Related]
14. A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond.
Pepe M; Hesami M; de la Cerda KA; Perreault ML; Hsiang T; Jones AMP
Biotechnol Adv; 2023 Dec; 69():108247. PubMed ID: 37659744
[TBL] [Abstract][Full Text] [Related]
15. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
Halberstadt AL; Koedood L; Powell SB; Geyer MA
J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.
Rosenblat JD; Leon-Carlyle M; Ali S; Husain MI; McIntyre RS
Am J Psychiatry; 2023 May; 180(5):395-396. PubMed ID: 36945824
[No Abstract] [Full Text] [Related]
17. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
Pearson C; Siegel J; Gold JA
J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
[TBL] [Abstract][Full Text] [Related]
18. Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain.
Kolbman N; Liu T; Guzzo P; Gilligan J; Mashour GA; Vanini G; Pal D
Curr Biol; 2023 Dec; 33(24):R1282-R1283. PubMed ID: 38113836
[TBL] [Abstract][Full Text] [Related]
19. [Classic psychedelic drugs and their potential therapeutic effect].
Bayat M
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis of the antidepressant action of the magic mushroom extract, psilocin.
Hakami Zanjani AA; Nguyen TQT; Jacobsen L; Khandelia H
Biochim Biophys Acta Proteins Proteom; 2023 Jul; 1871(4):140914. PubMed ID: 37019325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
